|By Marketwired .||
|July 14, 2014 09:36 AM EDT||
DUBLIN, IRELAND -- (Marketwired) -- 07/14/14 -- Research and Markets (http://www.researchandmarkets.com/research/6srq42/alzheimer_disease) has announced the addition of Jain PharmaBiotech's new report "Alzheimer Disease - New Drugs, Markets and Companies" to their offering.
Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.
Early diagnosis of Alzheimer's disease is an important first step in management. Several biomarkers in cerebrospinal fluid, blood and urine can detect the disease. They provide a valuable aid to the clinical examination and neuropsychological testing which are the main diagnostic methods supplemented by brain imaging. Genotyping, particularly of ApoE gene alleles is also useful in the evaluation of cases and planning management.
The current management of Alzheimer's disease is reviewed and it involves a multidisciplinary approach. Acetylcholinesterase inhibitors are mostly a symptomatic treatment but some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behavior and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer's disease is being recognized.
Research in Alzheimer's disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.
Over 300 different compounds are at various stages of development for the treatment of Alzheimer's disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. Selected 200 clinical trials are listed, of which 145 are still in progress and 55 were discontinued for various reasons.
Alzheimer's disease market in the seven major markets is analyzed for the year 2013. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2023. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.
Profiles of 145 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 97 collaborations. The bibliography contains over 890 publications that are cited in the report. The report is supplemented with 46 tables and 16 figures.
Key Topics Covered:
1. Clinical Features, Epidemiology and Pathology
2. Diagnostic Procedures for Alzheimer Disease
3. Management of Alzheimer Disease
4. Research in Alzheimer Disease
5. Drug Discovery & Development for Alzheimer Disease
6. Markets & Finances of AD Care
For more information visit http://www.researchandmarkets.com/research/6srq42/alzheimer_disease
Sector: Central Nervous System
Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Jul. 29, 2016 03:15 PM EDT Reads: 601
Jul. 29, 2016 03:00 PM EDT Reads: 369
Jul. 29, 2016 02:15 PM EDT Reads: 350
Jul. 29, 2016 02:00 PM EDT Reads: 1,200
Jul. 29, 2016 01:00 PM EDT Reads: 757
Jul. 29, 2016 01:00 PM EDT Reads: 699
Jul. 29, 2016 01:00 PM EDT Reads: 1,188
Jul. 29, 2016 01:00 PM EDT Reads: 2,093
Jul. 29, 2016 12:15 PM EDT Reads: 313
Jul. 29, 2016 12:00 PM EDT Reads: 1,830
Jul. 29, 2016 12:00 PM EDT Reads: 2,095
Jul. 29, 2016 11:30 AM EDT Reads: 1,251
Jul. 29, 2016 11:15 AM EDT Reads: 1,341
Jul. 29, 2016 11:15 AM EDT Reads: 678
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
Jul. 29, 2016 11:00 AM EDT Reads: 507